Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

MIDI Host microbe dialogue through metabolic interactions

Coordinator
The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
Runs
1 November 2026 to 31 October 2031
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101266308

What the project is doing

In the project's own words, from its summary on CORDIS.

The intestinal microbiome is a complex community of organisms that exists in symbiosis with its host. Microbiota perform essential digestive, metabolic, and immunomodulatory functions in health, and disturbance of the microbiota can contribute to disease. Microbial metabolites are a key ingredient in healthy host-microbe dialogue, bolstering barrier immunity and immune regulatory pathways. Our recent work on microbiota-derived small molecule metabolites ADP-heptose and the short chain fatty acid, butyrate, has identified new immune regulatory and microbicidal functions that could be targeted in inflammatory bowel disease.

However, harnessing metabolites as disease therapeutics has been challenging because of their diverse cellular targets and the complex bacterial community ecology governing their production and function. Using our recent technological advances we propose a multi-disciplinary approach spanning the frontiers of immunology, cell biology, gnotobiology, microbial ecology and computational biology, to deconvolute host microbiota interactions over space and time.

Using ADP-heptose and butyrate as exemplars, we will use metabolite-centric designer microbiome communities together with integrated spatial, omics-scale data in tissue sections, to chart the passage of microbiota-derived metabolites into tissue niches to reveal their cellular targets and influence on transcriptomic and proteomic networks relevant to immune regulatory and microbicidal function. In addition to our in vitro-defined cellular pathways, this will identify novel interkingdom targets and opportunities to treat disease niches, leaving other metabolic pathways and cellular interactions unaffected.

Results of these studies will be used to design new vaccine enhancing strategies and more specific therapeutic approaches in IBD patients.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI